UNICANCER

The HypoG-01 trial found 3-week hypofractionated radiotherapy noninferior to 5-week standard fractionation for nodal irradiation in breast cancer, with similar 5-year arm lymphedema incidence (33%). No detrimental effects on survival outcomes were observed, suggesting a potential shift to shorter radiotherapy regimens.

Short-term ADT with high-dose radiotherapy improves disease-free survival in localized prostate cancer, reducing biochemical failure risk without increasing toxicities.

A 3-week hypofractionated RT course showed noninferiority to 5-week normofractionated RT in reducing lymphedema risk in early-stage breast cancer, with similar survival outcomes and no increased toxicity, according to the HypoG-01 trial. The study concludes that 3-week nodal RT should be the standard for breast cancer treatment.

HypoG-01 trial at 2024 ESMO Congress found moderately hypofractionated locoregional radiation therapy noninferior to standard normofractionated therapy in lymphedema risk for early breast cancer patients, with no detrimental effects on survival or shoulder range of motion. The study recommends 3-week regimens for nodal radiotherapy.

The HypoG-01 study, led by Dr. Sofia Rivera, shows that a 3-week hypofractionated radiation therapy is equivalent to a 5-week normofractionated therapy for locoregional breast cancer, setting a new standard of care.

The ESMO 2024 annual congress in Barcelona features Gustave Roussy, a leading cancer research and treatment center, presenting key studies on breast cancer, thymus gland cancer, HR+/HER2- breast cancer, EGFR-mutant lung cancer, and soft tissue sarcomas. Gustave Roussy physicians also co-author studies on hormone-refractory prostate cancer and resistance to PDL1 inhibitors, and participate as session co-chairs and discussants.